Clobetasol propionate

Generic Name: Clobetasol propionate

Brand Names: Clobex, Clodan, Dermovate, Impeklo, Impoyz, Olux, Temovate, Tovet

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₂ClFO_₅

CAS Number: 25122-46-7

Unique Ingredient Identifier: 779619577M

Background: Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors. It has demonstrated superior activity compared to fluocinonide and was first described in the literature in 1974.

Clobetasol Propionate was granted FDA approval on 27 December 1985.

Indication: Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Associated Conditions: Alopecia, Severe Plaque psoriasis, Corticosteroid responsive, Inflammatory Dermatosis, Corticosteroid responsive, pruritic Dermatosis, Moderate Plaque psoriasis, Moderate Scalp Psoriasis, Severe Scalp Psoriasis

Clinical Trials

Evaluation of the Vasoconstriction Properties of MC2-01 Cream

Phase 1

Completed

Conditions: Vasoconstriction

Interventions: Drug: Clobetasol Propionate 0.05% Lotion
Drug: Desonide 0.05% Cream
Drug: MC2-01 Cream
Drug: Betamethasone Dipropionate 0.05% Cream
Drug: Triamcinolone Acetonide 0.1% Cream
Drug: Vehicle
Drug: Hydrocortisone Butyrate 0.1% Cream

First Posted Date: 2018-11-29

Last Posted Date: 2020-01-09

Lead Sponsor: MC2 Therapeutics

Target Recruit Count: 36

Registration Number: NCT03758365

Locations: 🇫🇷
CPCAD, Nice, France

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

Phase 2

Completed

Conditions: Oral Lichen Planus

Interventions: Drug: Clobetasol Propionate

First Posted Date: 2018-07-19

Last Posted Date: 2020-07-14

Lead Sponsor: Dermtreat

Target Recruit Count: 140

Registration Number: NCT03592342

Locations: 🇮🇪
Cork University Dental School and Hospital, Cork, Ireland
🇺🇸
QWay Research, Hialeah, Florida, United States
🇺🇸
University of Pennsylvania Health System, Dept. Oral amd Maxillofacial Surgery, Philadelphia, Pennsylvania, United States

and more 24 locations

Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata

Phase 4

Completed

Conditions: Alopecia Areata

Interventions: Drug: Minoxidil 5 % Topical Spray
Drug: Triamcinolone Acetonide
Drug: clobetasol propionate

First Posted Date: 2018-05-24

Last Posted Date: 2018-05-24

Lead Sponsor: Cairo University

Target Recruit Count: 40

Registration Number: NCT03535233

1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Clobetasol 0.05% ointment
Drug: Mapracorat (ZK 245186, BAY 86-5319)
Drug: Calcipotriene 0.005% ointment
Drug: Prednicarbate 0.25% ointment
Drug: Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment

First Posted Date: 2018-01-16

Last Posted Date: 2018-01-16

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT03399526

Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus

Phase 2

Completed

Conditions: Oral Lichen Planus

Interventions: Drug: Bifidobacterium animalis subsp. lactis HN019
Drug: Clobetasol propionate 0.05%

First Posted Date: 2017-12-29

Last Posted Date: 2020-03-27

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 22

Registration Number: NCT03386643

Locations: 🇧🇷
School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid

Phase 2

Terminated

Conditions: Bullous Pemphigoid

Interventions: Drug: Clobetasol 0.05% Topical Ointment
Drug: AC-203 1% Topical Ointment

First Posted Date: 2017-09-18

Last Posted Date: 2019-09-19

Lead Sponsor: TWi Biotechnology, Inc.

Target Recruit Count: 10

Registration Number: NCT03286582

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

Phase 2

Terminated

Conditions: Psoriasis

Interventions: Drug: DFD06

First Posted Date: 2017-06-07

Last Posted Date: 2024-03-07

Lead Sponsor: Primus Pharmaceuticals

Target Recruit Count: 22

Registration Number: NCT03179605

Locations: 🇺🇸
Site 104, Madera, California, United States
🇺🇸
Site 108, Santa Ana, California, United States
🇺🇸
Investigational Site 101, Lincoln, Nebraska, United States

and more 6 locations

Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus

Phase 2

Conditions: Oral Lichen Planus

Interventions: Drug: Clobetasol Propionate
Drug: Betamethasone Dipropionate

First Posted Date: 2017-01-20

Last Posted Date: 2018-03-14

Lead Sponsor: Garlapati Komali

Target Recruit Count: 30

Registration Number: NCT03026478

Locations: 🇮🇳
Komali Garlapati, Hyderabad, Telangana, India

BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: BAY1003803
Drug: Betamethasone/calcipotriene
Drug: Clobetasol propionate

First Posted Date: 2016-10-20

Last Posted Date: 2017-03-21

Lead Sponsor: Bayer

Target Recruit Count: 23

Registration Number: NCT02940002

BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

Phase 1

Terminated

Conditions: Psoriasis

Interventions: Drug: BAY1003803 0.01% lipophilic cream
Drug: Lipophilic cream vehicle
Drug: Clobetasol propionate
Drug: BAY1003803 0.1% lipophilic cream
Drug: Ointment vehicle
Drug: BAY1003803 0.01% ointment
Drug: BAY1003803 0.1% ointment

First Posted Date: 2016-10-18

Last Posted Date: 2017-11-08

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT02936492

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy